Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-4 inclisiran outcomes trial in atherosclerotic cardiovascular disease
ISRCTN88876914Phase 3Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Oct 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Inclisiran with Placebo (2 arms). Started Oct 2018; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on ISRCTN88876914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88876914.